Long intergenic non-protein coding RNA 1121 (LINC01121)

Long intergenic non-protein coding RNA 1121 (LINC01121) is a long non-coding RNA (lncRNA) that does not code for proteins and is located in intergenic regions of the genome. It is upregulated in several cancers, including breast and pancreatic cancer[1][2][3][4]. LINC01121 acts primarily through a *competing endogenous RNA (ceRNA) mechanism*, where it functions as a molecular sponge for microRNAs such as miR-150-5p, thereby indirectly regulating downstream targets like HMGA2, which are pivotal in cell proliferation, migration, invasion, and apoptosis suppression in cancer cells[1][3]. Studies show that LINC01121 knockdown suppresses proliferation, cell cycle progression, migration, and invasion while promoting apoptosis in breast cancer cells[1][3][4]. In pancreatic cancer, it similarly acts as an oncogene and appears to exert its effects through the repression of GLP1R and inhibition of cAMP/PKA signaling[2]. LINC01121 is not itself a druggable or classical therapeutic target such as a receptor or enzyme, but it represents a promising *biomarker* or possible future target for RNA-based cancer therapeutics. No approved drugs directly target LINC01121, and there are no well-established safety concerns for therapies targeting this molecule to date[1][2][3][4][5].

Other names

LINC01121UNQ6975NGNL6975